uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy : A Prospective Phase II Study. / Fosbol, Marie Obro; Mortensen, Jann; Petersen, Peter Meidahl; Loft, Annika; Madsen, Jacob; Kjaer, Andreas.
I: Diagnostics, Bind 11, Nr. 6, 1087, 2021.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy
T2 - A Prospective Phase II Study
AU - Fosbol, Marie Obro
AU - Mortensen, Jann
AU - Petersen, Peter Meidahl
AU - Loft, Annika
AU - Madsen, Jacob
AU - Kjaer, Andreas
PY - 2021
Y1 - 2021
N2 - The aim of this Phase II study was to investigate the potential for response assessment and prognostication of positron emission tomography (PET) using the ligand Ga-68-NOTA-AE105 targeting the urokinase-type plasminogen activator receptor (uPAR) in patients receiving Radium-223-dichloride therapy ((RaCl2)-Ra-223). A combined whole-body uPAR PET and computed tomography (CT) was performed before initiation of (RaCl2)-Ra-223 and after two cycles of therapy. Standardized uptake value (SUV) in selected bone metastases was measured and the lesion with the highest SUVmax was considered the index lesion. Clinical outcomes were overall survival (OS), radiographic progression free survival (rPFS) and occurrence of symptomatic skeletal event (SSE). A total of 17 patients were included and 14 patients completed both baseline and follow-up uPAR-PET/CT. Baseline SUVmax of the index lesion was associated with OS; hazard ratio 2.51 (95% CI: 1.01-6.28, p = 0.05) per unit increase in SUVmax. No association between changes in SUVmax from baseline to follow-up and OS, progression during therapy, or rPFS was found. Baseline SUVmax was a significant predictor of SSE with receiver operating characteristics (ROC) area under the curve (AUC) = 0.81 (95% CI: 0.58-1.00, p = 0.034). A cut-off for tumor SUVmax could be established with an odds ratio of 14.0 (95% CI: 1.14-172.6, p = 0.023) for occurrence of SSE within 12 months. Although based on a small number of patients, uPAR-PET SUVmax in bone metastases was predictive for OS and risk of SSE in mCRPC patients receiving (RaCl2)-Ra-223. However, a relatively low uptake of the uPAR ligand in bone metastases impedes visual evaluation and requires another modality for lesion delineation.
AB - The aim of this Phase II study was to investigate the potential for response assessment and prognostication of positron emission tomography (PET) using the ligand Ga-68-NOTA-AE105 targeting the urokinase-type plasminogen activator receptor (uPAR) in patients receiving Radium-223-dichloride therapy ((RaCl2)-Ra-223). A combined whole-body uPAR PET and computed tomography (CT) was performed before initiation of (RaCl2)-Ra-223 and after two cycles of therapy. Standardized uptake value (SUV) in selected bone metastases was measured and the lesion with the highest SUVmax was considered the index lesion. Clinical outcomes were overall survival (OS), radiographic progression free survival (rPFS) and occurrence of symptomatic skeletal event (SSE). A total of 17 patients were included and 14 patients completed both baseline and follow-up uPAR-PET/CT. Baseline SUVmax of the index lesion was associated with OS; hazard ratio 2.51 (95% CI: 1.01-6.28, p = 0.05) per unit increase in SUVmax. No association between changes in SUVmax from baseline to follow-up and OS, progression during therapy, or rPFS was found. Baseline SUVmax was a significant predictor of SSE with receiver operating characteristics (ROC) area under the curve (AUC) = 0.81 (95% CI: 0.58-1.00, p = 0.034). A cut-off for tumor SUVmax could be established with an odds ratio of 14.0 (95% CI: 1.14-172.6, p = 0.023) for occurrence of SSE within 12 months. Although based on a small number of patients, uPAR-PET SUVmax in bone metastases was predictive for OS and risk of SSE in mCRPC patients receiving (RaCl2)-Ra-223. However, a relatively low uptake of the uPAR ligand in bone metastases impedes visual evaluation and requires another modality for lesion delineation.
KW - urokinase-type plasminogen activator receptor (uPAR)
KW - prostate cancer
KW - PET
KW - Radium-223 therapy
KW - PLASMINOGEN-ACTIVATOR RECEPTOR
KW - IN-VITRO
KW - CONTRIBUTES
KW - EXPRESSION
KW - PEPTIDE
KW - DISEASE
KW - SYSTEM
KW - GROWTH
U2 - 10.3390/diagnostics11061087
DO - 10.3390/diagnostics11061087
M3 - Journal article
C2 - 34198666
VL - 11
JO - Diagnostics
JF - Diagnostics
SN - 2075-4418
IS - 6
M1 - 1087
ER -
ID: 274067456